|
Mar 22, 2021
|
Catalyst Pharmaceuticals Announces $40 Million Share Repurchase Program
CORAL GABLES, Fla. , March 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
|
|
|
Mar 15, 2021
|
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
- Firdapse ® Q4-20 Net Revenues of $31.0 Million , FY-20 Net Revenues of $119.1 Million - GAAP Net Income of $75.0 Million for Fiscal Year 2020 - $140.3 Million in Cash and Investments and No Funded Debt - Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow CORAL GABLES, Fla.
|
|
|
Mar 04, 2021
|
Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 16th, 2021
CORAL GABLES, Fla. , March 04, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
|
|
|
Feb 22, 2021
|
Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2021
Catalyst Supporting Facebook Live Panel on Living with a Rare Disease Hosted by The Mighty Catalyst Kicks off Rare Reason Campaign CORAL GABLES, Fla. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on
|
|
|
Jan 06, 2021
|
Catalyst Pharmaceuticals Announces Strategic Plan for Product Portfolio Expansion for Long-Term Success and Provides Corporate Update
Company to Expand R&D Focus for Pipeline Growth to include Earlier Stage Programs and Validated Technology Platforms Firdapse® 2020 Net Revenues Estimate of approximately $118 Million ; about 16% Increase From 2019 Ended 2020 with Estimated $140 Million in Cash and Investments Company Highlights
|
|
